A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.
- Resource Type
- Article
- Source
- Menopause (10723714); Aug2023, Vol. 30 Issue 8, p817-823, 7p
- Subject
- Language
- ISSN
- 10723714